BUSINESS BRIEFING / PHARMACEUTICALS
Times Wire Reports
Allergan Inc.’s promotions for the eyelash-growing drug Latisse are “misleading” because they don’t describe safety risks, regulators said.
The Food and Drug Administration cited the website www.latisse.com and a placard with a timeline of the product’s introduction in a warning letter to the Irvine company.
Allergan says the timeline is no longer being used.
Materials promoting a drug’s benefits must also address its risks, which in this case include allergic reactions or hair growth outside the treatment area, the FDA said.
